Linked Life Data

11877308

Source:http://linkedlifedata.com/resource/pubmed/id/11877308

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2002-3-5
pubmed:abstractText
Standard myeloablative conditioning prior to allogeneic hematopoietic stem cell (HSC) transplantation has been associated with significant toxicity in patients older than 45 years of age with myelofibrosis with myeloid metaplasia (MMM). We sought to evaluate the efficacy of a reduced-intensity conditioning regimen for allogeneic HSC transplantation in this setting. A regimen consisting of fludarabine (30 mg/m(2) intravenously daily for 5 days) and melphalan (70 mg/m(2) intravenously daily for 2 days) followed by transplantation of filgrastim-mobilized peripheral blood cells from HLA-identical siblings was administered to 4 older patients (median age, 56 years; range, 48-58 years) with advanced MMM. All patients achieved prompt neutrophil and platelet engraftment and have experienced a significant regression of splenomegaly and bone marrow fibrosis. All now have normal bone marrow cellularity. With a median follow-up of 13 months (range, 11-19 months), all 4 patients are alive with stable full-donor hematopoietic chimerism. These results support the feasibility and effectiveness of reduced-intensity conditioning prior to allogeneic HSC transplantation for older patients with advanced MMM.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0006-4971
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
99
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2255-8
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:11877308-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:11877308-Bone Marrow, pubmed-meshheading:11877308-Follow-Up Studies, pubmed-meshheading:11877308-Graft Survival, pubmed-meshheading:11877308-Hematopoietic Stem Cell Transplantation, pubmed-meshheading:11877308-Histocompatibility Testing, pubmed-meshheading:11877308-Humans, pubmed-meshheading:11877308-Male, pubmed-meshheading:11877308-Melphalan, pubmed-meshheading:11877308-Middle Aged, pubmed-meshheading:11877308-Primary Myelofibrosis, pubmed-meshheading:11877308-Splenomegaly, pubmed-meshheading:11877308-Transplantation, Homologous, pubmed-meshheading:11877308-Transplantation Chimera, pubmed-meshheading:11877308-Transplantation Conditioning, pubmed-meshheading:11877308-Treatment Outcome, pubmed-meshheading:11877308-Vidarabine
pubmed:year
2002
pubmed:articleTitle
Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia.
pubmed:affiliation
Blood and Marrow Transplantation Program, Section of Hematology/Oncology, University of Illinois College of Medicine, 840 South Wood Street, M/C 787, Chicago, IL 60612, USA. sdevine@uic.edu
pubmed:publicationType
Journal Article, Clinical Trial